Cargando…
Correction: Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515476/ https://www.ncbi.nlm.nih.gov/pubmed/34645673 http://dx.doi.org/10.1136/jitc-2020-001524corr1 |
Ejemplares similares
-
Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
por: Wen, Jing, et al.
Publicado: (2021) -
Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Publicado: (2022) -
Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
por: Niederwieser, Dietger, et al.
Publicado: (2020) -
Correction to Competing Interests
Publicado: (2023) -
Correction to: Complement in the pathogenesis of Alzheimer’s disease
por: Paul Morgan, B.
Publicado: (2018)